Androgen receptor gene aberrations in circulating cell-free DNA: Biomarkers of therapeutic resistance in castration-resistant prostate cancer

Clinical Cancer Research

Volumn 21, Issue 10, 2015, Pages 2315-2324

  Azad, Arun A ^a,b   Volik, Stanislav V ^a   Wyatt, Alexander W ^a   Haegert, Anne ^a   Le Bihan, Stephane ^a   Bell, Robert H ^a   Anderson, Shawn A ^a   McConeghy, Brian ^a   Shukin, Robert ^a   Bazov, Jenny ^a   Youngren, Jack ^c   Paris, Pamela ^c   Thomas, George ^d   Small, Eric J ^c   Wang, Yuzhuo ^a,e   Gleave, Martin E ^a,e   Collins, Colin C ^a,e   Chi, Kim N ^a,b,e  

^a VANCOUVER PROSTATE CENTRE   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; BICALUTAMIDE; CIRCULATING CELL FREE DNA; DNA; DOCETAXEL; ENZALUTAMIDE; FLUTAMIDE; NILUTAMIDE; ORTERONEL; PREDNISONE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ABIRATERONE; ANDROSTANE DERIVATIVE; TAXOID; TUMOR MARKER;

ADOLESCENT; AGED; AR GENE; ARTICLE; BLOOD SAMPLING; CASTRATION RESISTANT PROSTATE CANCER; CCND1 GENE; CCNE1 GENE; CHROMOSOME ABERRATION; CONTROLLED STUDY; DNA EXTRACTION; DNA HYBRIDIZATION; EXON; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MET GENE; MISSENSE MUTATION; ONCOGENE MYC; PRIORITY JOURNAL; BLOOD; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; GENETICS; HIGH THROUGHPUT SEQUENCING; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR EMBOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROSTENES; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; TAXOIDS;

EID: 84933510527     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2666     Document Type: Article

References (38)

1. Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol 2014;65:289-99.
2. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33.
3. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
4. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
5. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48.
6. Small EJ, Youngren J, Thomas G, Olson S, Toschi A, Foye A, et al. Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). J Clin Oncol 32:5s, 2014 (suppl; abstr 5020).
7. Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 2014;6: 254ra125.
8. Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013;3: 1020-9.
9. Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 2013;3:1030-43.
10. Chen E, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsivemutant androgen receptors. Clin Cancer Res 2014 Oct 15. [Epub ahead of print].
11. Schwarzenbach H, Alix-Panabieres C, Muller I, Letang N, Vendrell JP, Rebillard X, et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009;15: 1032-8.
12. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011;11:426-37.
13. Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med 2013;5:30.
14. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26:1148-59.
15. Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2014. Jan 31. [Epub ahead of print
16. Available from: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=ehgnwukmjpultoj&acc=GSE61134.
17. Shiota M, Bishop JL, Nip KM, Zardan A, Takeuchi A, Cordonnier T, et al. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res 2013;73:3109-19.
18. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
19. Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013;63:920-6.
20. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-43.
21. Waltering KK, Urbanucci A, Visakorpi T. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol 2012;360: 38-43.
22. Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev 2014;40:426-33.
23. Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun 2014;5:4988.
24. Duff J, McEwan IJ. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. Mol Endocrinol 2005;19:2943-54.
25. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 2002; 62:1496-502.
26. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997;3:1383-8.
27. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. ARV7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028-38.
28. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012;72:3457-62.
29. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010;107:16759-65.
30. Thomsen FB, Roder MA, Rathenborg P, Brasso K, Borre M, Iversen P. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand J Urol 2014;48:268-75.
31. Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 2015;67:23-9.
32. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24: 1802-7.
33. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, et al. Antitumour activity of abiraterone acetate against metastatic castrationresistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24:1807-12.
34. Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014;65:30-6.
35. Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 2014;50:78-84.
36. Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014;120: 968-75.
37. Cheng HH, Nadal R, Gulati R, Azad A, Twardowski P, Vaishampayan UN, et al. The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC. J Clin Oncol 32, 2014 (suppl 4; abstr 18).
38. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010;29:4018-32.